Menlo Therapeutics Inc.
(NASDAQ : MNLO)

( )
MNLO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Company
0.20%45.331.4%$886.97m
MRKMerck & Co., Inc.
1.55%74.600.6%$868.71m
PFEPfizer Inc.
1.13%39.420.9%$823.54m
JNJJohnson & Johnson
1.50%139.900.7%$815.75m
LLYEli Lilly and Company
1.74%117.481.0%$663.22m
ABBVAbbVie, Inc.
0.64%78.652.2%$407.28m
NVSNovartis AG Sponsored ADR
0.66%75.900.2%$278.63m
AZNAstraZeneca PLC Sponsored ADR
-0.16%38.691.3%$252.32m
GSKGlaxoSmithKline plc Sponsored ADR
1.34%40.210.2%$103.17m
NVONovo Nordisk A/S Sponsored ADR Class B
1.19%48.670.1%$67.15m
SNYSanofi Sponsored ADR
0.87%41.710.2%$36.01m
LCILannett Company, Inc.
-0.28%7.2036.7%$7.66m
AKTXAkari Therapeutics Plc Sponsored ADR
15.82%3.881.6%$5.73m
EPIXESSA Pharma Inc
-3.04%2.300.1%$0.03m

Company Profile

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.